China SXT Pharmaceuticals, Inc.(SXTC)Earnings, Financials & Key Ratios
SXTC•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryTraditional Chinese medicine producers
AboutChina SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.Show more
- Revenue$2M-9.7%
- EBITDA-$3M-12.4%
- Net Income-$3M-6.6%
- EPS (Diluted)-8.18-129.1%
- Gross Margin21.11%-26.5%
- EBITDA Margin-149.24%-24.5%
- Operating Margin-153.97%-18.1%
- Net Margin-189.77%-18.1%
- ROE-22.5%-3.9%
SXTC Key Insights
China SXT Pharmaceuticals, Inc. (SXTC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Share count reduced 53.4% through buybacks
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 11 (bottom 11%)
- ✗Sales declining 19.5% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SXTC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SXTC Price & Volume
China SXT Pharmaceuticals, Inc. (SXTC) stock price & volume — 10-year historical chart
Loading chart...
SXTC Growth Metrics
China SXT Pharmaceuticals, Inc. (SXTC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-19.54%
3 Years-12.54%
TTM-27.41%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM58.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM76.69%
Return on Capital
10 Years16.12%
5 Years-24.02%
3 Years-23.58%
Last Year-17.94%
SXTC Peer Comparison
China SXT Pharmaceuticals, Inc. (SXTC) competitors in Traditional Chinese medicine producers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SBFM | 1.07M | 2.13 | -0.15 | 4.11% | -17.01% | -25.58% | 0.04 | |
 CHNR | 41.53M | 4.30 | -88.11 | -15.72% | ||||
 TCMD | 600.45M | 26.62 | 32.46 | 12.47% | 5.91% | 9.7% | 0.07 | |
 CODA | 112.81M | 10.00 | 27.03 | 30.75% | 17.66% | 8.33% | 0.01 | |
 CCRN | 425.82M | 13.17 | -4.49 | -21.56% | -9.84% | -27.1% | 0.01 | |
 NVO | 191.93B | 43.19 | 12.18 | 6.43% | 37.2% | 66.36% | 0.67 | |
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 |
Compare SXTC vs Peers
China SXT Pharmaceuticals, Inc. (SXTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SXTC Income Statement
China SXT Pharmaceuticals, Inc. (SXTC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 4.88M | 7.02M | 7.01M | 5.16M | 4.78M | 2.6M | 1.97M | 1.93M | 1.74M |
Revenue Growth % | 31.27% | 43.79% | -0.1% | -26.38% | -7.45% | -45.53% | -24.23% | -2.19% | -9.73% |
Cost of Goods Sold | 2.57M | 3.62M | 2.4M | 2.46M | 1.94M | 1.35M | 1.55M | 1.37M | 1.37M |
COGS % of Revenue | 52.64% | 51.54% | 34.23% | 47.63% | 40.56% | 51.9% | 78.38% | 71.27% | 78.89% |
Gross Profit | 2.31M▲ 0% | 3.4M▲ 47.1% | 4.61M▲ 35.6% | 2.7M▼ 41.4% | 2.84M▲ 5.0% | 1.25M▼ 55.9% | 426.27K▼ 65.9% | 553.97K▲ 30.0% | 367.43K▼ 33.7% |
Gross Margin % | 47.36% | 48.46% | 65.77% | 52.37% | 59.44% | 48.1% | 21.62% | 28.73% | 21.11% |
Gross Profit Growth % | 191.19% | 47.12% | 35.57% | -41.37% | 5.02% | -55.92% | -65.94% | 29.96% | -33.67% |
Operating Expenses | 709.82K | 1.77M | 2.84M | 4.04M | 5.04M | 6.44M | 6.03M | 3.07M | 3.05M |
OpEx % of Revenue | 14.54% | 25.21% | 40.53% | 78.35% | 105.42% | 247.53% | 306.02% | 159.15% | 175.08% |
Selling, General & Admin | 709.82K | 1.77M | 2.84M | 4.04M | 5.04M | 6.44M | 6.03M | 3.07M | 3.05M |
SG&A % of Revenue | 14.54% | 25.21% | 40.53% | 78.35% | 105.42% | 247.53% | 306.02% | 159.15% | 175.08% |
Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 184.19K | 191.39K |
R&D % of Revenue | - | - | - | - | - | - | - | 9.55% | 10.99% |
Other Operating Expenses | 0 | -3.8K | 27.14K | 0 | 0 | 0 | 0 | -184.19K | -191.39K |
Operating Income | 1.6M▲ 0% | 1.63M▲ 1.9% | 1.77M▲ 8.4% | 4.28M▲ 142.1% | -2.2M▼ 151.3% | -5.19M▼ 136.2% | -5.61M▼ 8.1% | -2.52M▲ 55.1% | -2.68M▼ 6.6% |
Operating Margin % | 32.82% | 23.25% | 25.24% | 83% | -45.99% | -199.43% | -284.4% | -130.42% | -153.97% |
Operating Income Growth % | 666.08% | 1.88% | 8.41% | 142.15% | -151.28% | -136.21% | -8.05% | 55.15% | -6.57% |
EBITDA | 1.7M | 1.76M | 1.95M | 4.62M | -1.85M | -4.87M | -5.36M | -2.31M | -2.6M |
EBITDA Margin % | 34.85% | 25.1% | 27.82% | 89.43% | -38.76% | -187.13% | -271.72% | -119.88% | -149.24% |
EBITDA Growth % | 470.74% | 3.54% | 10.71% | 136.7% | -140.11% | -162.99% | -10.01% | 56.84% | -12.38% |
D&A (Non-Cash Add-back) | 99.23K | 129.44K | 180.92K | 331.84K | 345.41K | 320.01K | 250.16K | 203.25K | 82.3K |
EBIT | 1.6M | 1.63M | 1.8M | -1.34M | -2.2M | -5.37M | -5.46M | -2.55M | -2.66M |
Net Interest Income | -40.39K | -779 | -5.17K | -3.35M | -1.62M | -36.7K | -476.78K | -544.28K | -648.22K |
Interest Income | 0 | 0 | 5.17K | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 40.39K | 779 | 5.17K | 3.35M | 1.62M | 36.7K | 476.78K | 544.28K | 648.22K |
Other Income/Expense | -21.99K | -4.58K | 21.97K | -9.05M | -743.79K | -218.28K | -327.26K | -583.32K | -623.17K |
Pretax Income | 1.58M▲ 0% | 1.63M▲ 3.0% | 1.79M▲ 10.1% | -10.39M▼ 680.0% | -2.94M▲ 71.7% | -5.41M▼ 83.9% | -5.93M▼ 9.7% | -3.1M▲ 47.8% | -3.3M▼ 6.6% |
Pretax Margin % | 32.37% | 23.19% | 25.55% | -201.26% | -61.56% | -207.82% | -301% | -160.67% | -189.77% |
Income Tax | 395.05K | 440.1K | 252.23K | -101.72K | -192.68K | 328.15K | 0 | 0 | 0 |
Effective Tax Rate % | 25% | 27.04% | 14.08% | 0.98% | 6.55% | -6.07% | 0% | 0% | 0% |
Net Income | 1.19M▲ 0% | 1.19M▲ 0.2% | 1.54M▲ 29.6% | -10.29M▼ 768.4% | -2.75M▲ 73.3% | -5.74M▼ 108.7% | -5.93M▼ 3.5% | -3.1M▲ 47.8% | -3.3M▼ 6.6% |
Net Margin % | 24.28% | 16.92% | 21.95% | -199.29% | -57.52% | -220.43% | -301% | -160.67% | -189.77% |
Net Income Growth % | 737.3% | 0.21% | 29.61% | -768.38% | 73.29% | -108.72% | -3.46% | 47.79% | -6.62% |
Net Income (Continuing) | 1.19M | 1.19M | 1.54M | -10.29M | -2.75M | -5.74M | -5.93M | -3.1M | -3.3M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.00▲ 0% | 0.00▲ 0% | 149.67▲ 0% | -832.08▼ 655.9% | -95.48▲ 88.5% | -137.92▼ 44.4% | -22.23▲ 83.9% | -3.57▲ 83.9% | -8.18▼ 129.1% |
EPS Growth % | - | - | - | -655.94% | 88.53% | -44.45% | 83.88% | 83.94% | -129.13% |
EPS (Basic) | 0.00 | 0.00 | 149.67 | -832.08 | -95.48 | -137.92 | -22.23 | -3.57 | -8.18 |
Diluted Shares Outstanding | 0 | 0 | 10.28K | 12.36K | 28.78K | 41.59K | 266.97K | 867.42K | 403.92K |
Basic Shares Outstanding | 0 | 0 | 10.28K | 12.36K | 28.78K | 41.59K | 266.97K | 867.42K | 403.92K |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
SXTC Balance Sheet
China SXT Pharmaceuticals, Inc. (SXTC) balance sheet — assets, liabilities & shareholders' equity
| Metric | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 4.91M | 6.1M | 15.59M | 19.64M | 23.23M | 22.45M | 19.52M | 14.23M | 21.3M |
Cash & Short-Term Investments | 65.57K | 560.25K | 9.13M | 7.29M | 13.33M | 15.52M | 17.37M | 12.07M | 18.1M |
Cash Only | 65.57K | 560.25K | 9.13M | 7.29M | 13.33M | 15.52M | 17.37M | 12.07M | 18.1M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 3.21M | 3.91M | 4.93M | 10.65M | 7.77M | 5.53M | 1.34M | 1.35M | 1.9M |
Days Sales Outstanding | 239.72 | 203.48 | 256.75 | 752.83 | 593.38 | 775.01 | 248.91 | 254.83 | 398.39 |
Inventory | 1.02M | 1.27M | 1.01M | 892.77K | 859.7K | 1.02M | 531.25K | 809.76K | 828.05K |
Days Inventory Outstanding | 144.66 | 127.82 | 153.26 | 132.54 | 161.91 | 274.98 | 125.47 | 215.03 | 220.05 |
Other Current Assets | 615.15K | 134.73K | 197.8K | 654.96K | 754.12K | 384.55K | 230.64K | 6.84K | 30.41K |
Total Non-Current Assets | 526.3K | 1.56M | 1.88M | 2.07M | 11.31M | 11.09M | 10.03M | 8.89M | 367.02K |
Property, Plant & Equipment | 485.29K | 1.49M | 1.81M | 1.9M | 1.79M | 1.59M | 1.27M | 564.69K | 355.21K |
Fixed Asset Turnover | 10.06x | 4.71x | 3.88x | 2.71x | 2.67x | 1.64x | 1.55x | 3.42x | 4.90x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 41K | 60.67K | 61.1K | 50.05K | 45.8K | 38.76K | 27.87K | 19.1K | 11.81K |
Long-Term Investments | 0 | -6.17K | -13.5K | -441.21K | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 6.17K | 13.5K | 441.21K | 9.16M | 9.46M | 8.74M | 8.31M | 0 |
Total Assets | 5.43M▲ 0% | 7.66M▲ 41.0% | 17.47M▲ 128.1% | 21.7M▲ 24.2% | 34.55M▲ 59.2% | 33.55M▼ 2.9% | 29.55M▼ 11.9% | 23.13M▼ 21.7% | 21.66M▼ 6.3% |
Asset Turnover | 0.90x | 0.92x | 0.40x | 0.24x | 0.14x | 0.08x | 0.07x | 0.08x | 0.08x |
Asset Growth % | -13.75% | 40.99% | 128.14% | 24.22% | 59.19% | -2.9% | -11.9% | -21.75% | -6.33% |
Total Current Liabilities | 3.58M | 4.37M | 6.32M | 12.26M | 18.58M | 17.12M | 14.5M | 8.9M | 6.01M |
Accounts Payable | 1.26M | 2.41M | 1.69M | 1.94M | 1.46M | 1.48M | 1.38M | 1.28M | 1.16M |
Days Payables Outstanding | 179.63 | 242.88 | 256.27 | 288.18 | 274.3 | 400.55 | 325.43 | 339.77 | 307.82 |
Short-Term Debt | 302.17K | 385.12K | 261.15K | 6.69M | 37.12K | 2.05M | 3.33M | 2.29M | 710.97K |
Deferred Revenue (Current) | 0 | 292.95K | 57.55K | 298.04K | 257.45K | 77.37K | 165.53K | 187.66K | 58.63K |
Other Current Liabilities | 1.67M | 1.27M | 3.03M | 1.96M | 15.2M | 122.77K | 7.84M | 3.06M | 728.28K |
Current Ratio | 1.37x | 1.40x | 2.47x | 1.60x | 1.25x | 1.31x | 1.35x | 1.60x | 3.54x |
Quick Ratio | 1.09x | 1.11x | 2.31x | 1.53x | 1.20x | 1.25x | 1.31x | 1.51x | 3.40x |
Cash Conversion Cycle | 204.75 | 88.42 | 153.74 | 597.19 | 480.99 | 649.44 | 48.96 | 130.09 | 310.63 |
Total Non-Current Liabilities | 0 | 0 | 41.71K | 36.51K | 6.29K | 0 | 365.82K | 294.67K | 211.68K |
Long-Term Debt | 0 | 0 | 41.71K | 36.51K | 6.29K | 0 | 117.86K | 117.13K | 96.26K |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 247.96K | 177.54K | 115.42K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3.58M | 4.37M | 6.36M | 12.3M | 18.59M | 17.12M | 14.86M | 9.2M | 6.22M |
Total Debt | 302.17K | 385.12K | 261.15K | 6.72M | 43.41K | 2.05M | 3.76M | 2.65M | 983.88K |
Net Debt | 236.6K | -175.13K | -8.87M | -563.16K | -13.29M | -13.48M | -13.61M | -9.42M | -17.12M |
Debt / Equity | 0.16x | 0.12x | 0.02x | 0.72x | 0.00x | 0.12x | 0.26x | 0.19x | 0.06x |
Debt / EBITDA | 0.18x | 0.22x | 0.13x | 1.46x | - | - | - | - | - |
Net Debt / EBITDA | 0.14x | -0.10x | -4.55x | -0.12x | - | - | - | - | - |
Interest Coverage | 39.67x | 2095.34x | 342.00x | 1.28x | -1.36x | -141.43x | -11.76x | -4.62x | -4.14x |
Total Equity | 1.85M▲ 0% | 3.29M▲ 77.4% | 11.11M▲ 238.1% | 9.4M▼ 15.4% | 15.96M▲ 69.8% | 16.42M▲ 2.9% | 14.69M▼ 10.6% | 13.93M▼ 5.2% | 15.44M▲ 10.8% |
Equity Growth % | 149.42% | 77.36% | 238.06% | -15.36% | 69.78% | 2.9% | -10.55% | -5.18% | 10.83% |
Book Value per Share | - | - | 1080.10 | 760.38 | 554.56 | 394.91 | 55.03 | 16.06 | 38.22 |
Total Shareholders' Equity | 1.85M | 3.29M | 11.11M | 9.4M | 15.96M | 16.42M | 14.69M | 13.93M | 15.44M |
Common Stock | 20K | 20K | 22.71K | 34.67K | 62.06K | 162.47K | 913.78K | 4.35M | 44.53M |
Retained Earnings | 357.06K | 1.54M | 3.08M | -7.2M | -9.95M | -15.69M | -21.61M | -24.71M | -28.02M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 11.82K | 257.37K | 50.4K | -590.66K | 527.79K | 956.14K | -197.57K | -1.03M | -1.08M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SXTC Cash Flow Statement
China SXT Pharmaceuticals, Inc. (SXTC) cash flow — operating, investing & free cash flow history
| Metric | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 293.04K | 1.92M | 239.19K | 934.25K | -1.32M | 268.29K | -80.76K | -1.93M | -2.35M |
Operating CF Margin % | 6% | 27.36% | 3.41% | 18.1% | -27.56% | 10.31% | -4.1% | -99.98% | -134.72% |
Operating CF Growth % | 60.6% | 555.25% | -87.54% | 290.58% | -240.92% | 120.38% | -130.1% | -2287.47% | -21.64% |
Net Income | 1.19M | 1.19M | 1.54M | -7.94M | -2.75M | -5.74M | -5.93M | -3.1M | -3.3M |
Depreciation & Amortization | 99.23K | 129.44K | 180.92K | 331.84K | 345.41K | 320.01K | 250.16K | 203.25K | 82.3K |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 2.33M | 554.57K | 352.1K | 0 |
Deferred Taxes | 0 | -5.85K | -7.72K | -101.72K | -192.68K | 328.15K | 3.23M | 0 | 0 |
Other Non-Cash Items | 1.44M | -2 | 66.89K | 6.7M | 2.89M | 1.12M | 408.69K | 996.69K | 1.85M |
Working Capital Changes | -991.33K | 608.99K | -1.54M | 1.95M | -1.61M | 1.9M | 1.42M | -381.56K | -971.74K |
Change in Receivables | -942.97K | 384.43K | -1.81M | 104K | -519.24K | 831.47K | 912.95K | -321.42K | -480.56K |
Change in Inventory | 384.22K | -274.38K | 177.64K | 39.71K | 38.62K | -180.8K | 408.95K | -190.29K | -14.53K |
Change in Payables | -1.47M | 966.57K | -567.31K | 302.27K | -619.54K | -22.79K | 9.7K | -29.25K | -114.08K |
Cash from Investing | -186.31K | -1.14M | -610.09K | -5.5M | -5.81M | -46.91K | -12.3K | 26.42K | 63.52K |
Capital Expenditures | -186.31K | -1.05M | -610.09K | -406.66K | -93.04K | -62.49K | -70.68K | -7.06K | -2.02K |
CapEx % of Revenue | 3.82% | 14.97% | 8.7% | 7.88% | 1.95% | 2.4% | 3.58% | 0.37% | 0.12% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -7.13K | -92.42K | -11.28K | -1.5M | 3.13M | 15.58K | 58.38K | 33.49K | 65.54K |
Cash from Financing | -50.56K | -314.22K | 9.04M | 3.02M | 12.41M | 1.6M | 2.94M | -2.62M | 8.4M |
Debt Issued (Net) | 0 | -314.22K | 69.49K | 8.8M | -124.95K | 2.77M | 4M | 1.31M | -65.11K |
Equity Issued (Net) | 0 | 0 | 1000K | 0 | 0 | 1000K | 1000K | 0 | 1000K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -50.56K | 0 | 2.48M | -5.78M | 12.53M | -4.29M | -3.26M | -3.93M | 5.7M |
Net Change in Cash | 54.13K▲ 0% | 494.68K▲ 813.9% | 8.63M▲ 1645.4% | -2M▼ 123.2% | 6.07M▲ 402.9% | 2.21M▼ 63.6% | 1.8M▼ 18.6% | -5.29M▼ 394.1% | 6.05M▲ 214.4% |
Free Cash Flow | 106.73K▲ 0% | 869.44K▲ 714.6% | -370.89K▼ 142.7% | 527.59K▲ 242.2% | -1.41M▼ 367.2% | 205.8K▲ 114.6% | -151.44K▼ 173.6% | -1.94M▼ 1177.8% | -2.35M▼ 21.3% |
FCF Margin % | 2.19% | 12.39% | -5.29% | 10.22% | -29.5% | 7.91% | -7.68% | -100.34% | -134.84% |
FCF Growth % | 24.86% | 714.58% | -142.66% | 242.25% | -367.18% | 114.6% | -173.59% | -1177.8% | -21.3% |
FCF per Share | - | - | -36.07 | 42.67 | -48.98 | 4.95 | -0.57 | -2.23 | -5.81 |
FCF Conversion (FCF/Net Income) | 0.25x | 1.62x | 0.16x | -0.09x | 0.48x | -0.05x | 0.01x | 0.62x | 0.71x |
Interest Paid | 197 | 0 | 1.49K | 287.81K | 5.55K | 3.2K | 0 | 0 | 21.24K |
Taxes Paid | 7.09K | 22.36K | 51.76K | 10.36K | 3.08K | 16.73K | 0 | 0 | 0 |
SXTC Key Ratios
China SXT Pharmaceuticals, Inc. (SXTC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 19.06% | 91.33% | 46.22% | 21.39% | -100.32% | -21.67% | -35.42% | -38.15% | -21.65% | -22.5% |
Return on Invested Capital (ROIC) | 12.96% | 72.83% | 47.09% | 49.62% | 58.03% | -28.63% | -138.55% | -208.91% | -67.53% | -141.97% |
Gross Margin | 21.35% | 47.36% | 48.46% | 65.77% | 52.37% | 59.44% | 48.1% | 21.62% | 28.73% | 21.11% |
Net Margin | 3.81% | 24.28% | 16.92% | 21.95% | -199.29% | -57.52% | -220.43% | -301% | -160.67% | -189.77% |
Debt / Equity | 0.65x | 0.16x | 0.12x | 0.02x | 0.72x | 0.00x | 0.12x | 0.26x | 0.19x | 0.06x |
Interest Coverage | - | 39.67x | 2095.34x | 342.00x | 1.28x | -1.36x | -141.43x | -11.76x | -4.62x | -4.14x |
FCF Conversion | 1.29x | 0.25x | 1.62x | 0.16x | -0.09x | 0.48x | -0.05x | 0.01x | 0.62x | 0.71x |
Revenue Growth | - | 31.27% | 43.79% | -0.1% | -26.38% | -7.45% | -45.53% | -24.23% | -2.19% | -9.73% |
Related:SXTC Dividend History·SXTC Revenue History·SXTC Price History·SXTC P/E History·SXTC Financial Ratios·SXTC Institutional Holders
SXTC Frequently Asked Questions
China SXT Pharmaceuticals, Inc. (SXTC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
China SXT Pharmaceuticals, Inc. (SXTC) reported $1.7M in revenue for fiscal year 2025. This represents a 53% decrease from $3.7M in 2016.
China SXT Pharmaceuticals, Inc. (SXTC) saw revenue decline by 9.7% over the past year.
China SXT Pharmaceuticals, Inc. (SXTC) reported a net loss of $3.3M for fiscal year 2025.
Dividend & Returns
China SXT Pharmaceuticals, Inc. (SXTC) has a return on equity (ROE) of -22.5%. Negative ROE indicates the company is unprofitable.
China SXT Pharmaceuticals, Inc. (SXTC) had negative free cash flow of $2.3M in fiscal year 2025, likely due to heavy capital investments.